Kainate-type glutamate receptor (KAR) (KAR)

Kainate-type glutamate receptors (KARs) are a distinct class of ionotropic glutamate receptors that mediate fast excitatory neurotransmission and modulate synaptic plasticity throughout the central nervous system (StatPearls, 2023). They are formed by the tetrameric assembly of five subunits, GRIK1 through GRIK5, which determine the receptor's biophysical properties and pharmacological profile (UniProt, 2024). Unlike other glutamate receptors, KARs function both postsynaptically to mediate excitatory currents and presynaptically to regulate the release of both excitatory and inhibitory neurotransmitters (IUPHAR/BPS, 2023). This dual role allows them to fine-tune the balance of excitation and inhibition within neural circuits. Dysregulation of KAR signaling is strongly linked to the pathophysiology of epilepsy, where overactivation can trigger seizures, as well as psychiatric conditions like schizophrenia and depression (PubMed, 2022). Consequently, KARs are significant therapeutic targets for anticonvulsants and neuroprotective agents, though achieving subunit specificity remains a primary challenge in drug development (Nature Reviews Neuroscience, 2021). In addition to their ionotropic effects, some KARs exhibit metabotropic signaling properties, further complicating their role in neuronal signaling (PubMed, 2020). Research into KAR-selective ligands continues to expand, aiming to treat chronic pain and neurodegenerative disorders without the side effects associated with broader glutamate receptor inhibition.

Other names

Kainate receptorIonotropic glutamate receptor kainate typeGRIKiGluRGlutamate receptor ionotropic kainate

Kainate receptors function as ligand-gated ion channels that open in response to glutamate binding, allowing the influx of sodium and potassium ions to depolarize the neuron (IUPHAR/BPS, 2023). Pharmacological intervention involves competitive antagonism to block the glutamate binding site, non-competitive antagonism to inhibit the ion channel pore, or allosteric modulation to alter receptor kinetics and reduce excitatory drive (PubMed, 2021). Some agents also target the receptor's presynaptic role to modulate the release of other neurotransmitters (Nature Reviews Neuroscience, 2021).